5
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T0373L | Erlotinib hydrochloride | OSI-744,NSC 718781,Erlotinib HCl,CP-358774 | EGFR , Autophagy |
Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer. | |||
T11229 | Erlotinib-d6 | OSI-774 D6,NSC 718781 D6,CP-358774 D6 | Others |
Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6 is a deuterium labeled Erlotinib . | |||
T19312 | Erlotinib-d6 hydrochloride | CP-358774 D6 hydrochloride,NSC 718781 D6 hydrochloride,Erlotinib D6 hydrochloride,OSI-774 D6 hydrochloride | Others |
Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM. Erlotinib D6 hydrochloride a deuterium labeled Erlotinib Hydrochloride. | |||
T0373 | Erlotinib | OSI-744,NSC 718781,CP358774,R1415 | EGFR , Autophagy |
Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer. | |||
T0373L1 | Erlotinib mesylate | CP-358774,CP-358,774,OSI-774,CP358774,OSI 774 | |
Erlotinib is an epidermal growth factor receptor inhibitor. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. |